연구성과로 돌아가기

2023 연구자 정보 (144 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Morozov, Viacheslav
(Morozov, V)
Hepatolog Med Co, Samara, Russia

[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Mu, Quanhua
(Mu, QH)
Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Kowloon, Clear Water Bay, Hong Kong, Peoples R China JKI-6568-2023
Mu, Quanhua

[JCR상위 4.5] Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma SCIE 4.5 GENETICS & HEREDITY nsproper@naver.com;benedict.yoon@samsung.com;jgwang@ust.hk;
Nam, Yoonhee
(Nam, Y)
제1저자 Hong Kong Univ Sci & Technol, Div Life Sci, Kowloon, Clear Water Bay, Hong Kong, Peoples R China
Hong Kong Univ Sci & Technol, State Key Lab Mol Neurosci, Kowloon, Clear Water Bay, Hong Kong, Peoples R China


[JCR상위 4.5] Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma SCIE 4.5 GENETICS & HEREDITY nsproper@naver.com;benedict.yoon@samsung.com;jgwang@ust.hk;
Oh, Jeong-Woo
(Oh, JW)
Samsung Med Ctr, Inst Refractory Canc Res, Res Inst Future Med, Seoul, South Korea

[JCR상위 4.5] Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma SCIE 4.5 GENETICS & HEREDITY nsproper@naver.com;benedict.yoon@samsung.com;jgwang@ust.hk;
Pacurar, Daniela
(Pacurar, D)
Carol Davila Univ Med & Pharm, Bucharest, Romania IYS-1131-2023
Pacurar, Daniela

[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Paff, Melanie
(Paff, M)
GSK, Collegeville, PA USA

[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report
SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY robert.c.elston@gsk.com;
Park, JeongSu
(Park, J)
제1저자 Chungbuk Natl Univ, Cheongju, South Korea

[JCR상위 4.5] ALPHA-1 ANTITRYPSIN/ PROTEINASE 3 IMBALANCE EXERTS PROTEOLYTIC REGULATION ON INTERLEUKIN-32 GAMMA TO PROMOTE NONALCOHOLIC STEATOHEPATITIS SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Park, Jin Kyung
(Park, JK)
Ildong Pharmaceut Co, Seoul, South Korea

[JCR상위 4.5] DECREASED RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH BESIFOVIR SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Park, Min Kyung
(Park, MK)
Seoul Natl Univ, Coll Med, Seoul, South Korea
Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
Seoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea


[JCR상위 4.5] PROTON PUMP INHIBITOR TREATMENT IS ASSOCIATED WITH A HIGHER MORTALITY IN CIRRHOTIC PATIENTS: A MULTICENTER STUDY
[JCR상위 8.7] Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study
SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY mhhur@snu.ac.kr;alsrud627@snu.ac.kr;terryfungyip@gmail.com;e580306@ms31.hinet.net;vital@snu.ac.kr;dr.choi85@gmail.com;KSUKOREA@yuhs.ac;limys@amc.seoul.kr;psyoung0419@gmail.com;wonglaihung@mect.cuhk.edu.hk;sinndhn@gmail.com;jyj412@hanmail.net;sekim@hallym.or.kr;cypeng@mail.cmuh.org.tw;drshp@khu.ac.kr;5137ccy@gmail.com;hwiyoung@gmail.com;amelia86@naver.com;gandorie@gmail.com;noshin@hanyang.ac.kr;mseileen80@hanyang.ac.kr;sonjh@hanyang.ac.kr;dr486@eulji.ac.kr;jshim3927@gmail.com;jeongsw@schmc.ac.kr;choyk2004.cho@samsung.com;hskim@kdh.or.kr;mjjang2014@naver.com;yoonjun@snu.ac.kr;yoonjh@snu.ac.kr;pindra@empal.com;
Park, Seung Ha
(Park, SH)
Inje Univ, Haeundae Paik Hosp, Gimhae, South Korea

[JCR상위 4.5] HCC PREDICTION MODELS EFFECTIVELY ASSESS THE RISK OF HCC IN CHRONIC HEPATITIS C PATIENTS WITHOUT ADVANCED FIBROSIS AFTER ORAL ANTIVIRAL THERAPY: A MULTICENTER STUDY SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Park, Sung Jae
(Park, SJ)
Inje Univ, Coll Med, Gimhae, South Korea

[JCR상위 4.5] PROTON PUMP INHIBITOR TREATMENT IS ASSOCIATED WITH A HIGHER MORTALITY IN CIRRHOTIC PATIENTS: A MULTICENTER STUDY
[JCR상위 4.5] DECREASED RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH BESIFOVIR
SCIE 4.5 GASTROENTEROLOGY & HEPATOLOGY
Park, Woong-Yang
(Park, WY)
Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea
Samsung Med Ctr, Samsung Genome Inst, Seoul, South Korea


[JCR상위 4.5] Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma SCIE 4.5 GENETICS & HEREDITY nsproper@naver.com;benedict.yoon@samsung.com;jgwang@ust.hk;
Park, Young Joo
(Park, YJ)
Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea
Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea
Pusan Natl Univ Hosp, Busan, South Korea


[JCR상위 4.5] REAL-WORLD EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB COMBINATION TREATMENT IN HIGH-RISK PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
[JCR상위 1.7] Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma
SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY jheo@pusan.ac.kr;
Piratvisuth, Teerha
(Piratvisuth, T)
Nkc Inst Gastroenterol & Hepatol, Songkhla, Thailand
NKC Inst Gastroenterol & Hepatol, Songkhla, Thailand


[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report
SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY robert.c.elston@gsk.com;
Quinn, Geoff
(Quinn, G)
GSK, Stevenage, Herts, England

[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report
SCIE 1.7 GASTROENTEROLOGY & HEPATOLOGY robert.c.elston@gsk.com;
페이지 이동: